Takeda Receives Grant from Bill & Melinda Gates Foundation
Takeda received a $38 million grant from the Bill & Melinda Gates Foundation to develop, license, and supply Sabin-strain inactivated poliovirus to more than 70 developing countries.
Takeda Pharmaceutical Company Limited and the Bill & Melinda Gates Foundation announced they have entered into a partnership to support polio eradication in developing countries, Takeda said in a May 9, 2016 press announcement. The Bill & Melinda Gates Foundation has provided Takeda with a $38 million grant to develop, license, and supply at least 50 million doses per year of Sabin-strain inactivated poliovirus vaccine (sIPV) to more than 70 developing countries. The vaccine will be manufactured at Takeda’s facility in Hikari, Japan.
Under the terms of the agreement, the Gates Foundation will provide the grant to Takeda to make doses of a Sabin-strain inactivated polio vaccine to developing countries receiving Gavi support. Gavi, the Vaccine Alliance, brings together public and private sectors with the goal of creating equal access to new and underused vaccines for children living in the world’s poorest countries, Takeda said in a press announcement. Takeda’s sIPV was originally licensed from the Japan Polio Research Institute, which is now a part of BIKEN.
Source: Takeda
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
